Prevalence of hepatitis B and C viruses infections among hemodialysis patients in Addis Ababa, Ethiopia

Corresponding Author:

Juhar SK
MSc in Diagnostic and Public Health Microbiology, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
E-mail: umehughes@yahoo.com

Abstract

Background: HBV and HCV infections are the most important causes of morbidity and mortality in haemodialysis patients. Hepatitis viruses cause potentially life-threatening inflammation of the liver, characterized by acute and chronic forms of liver disease. The prevalence of hepatitis B virus (HBV) antigen and Anti- hepatitis C virus (HCV) antibody among haemodialysis (HD) patients in Addis Ababa was investigated using ELISA test method. The aim of this study was to assess the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV).

Methodology: Cross-sectional study was done in a total of 253 (188 male and 65 female) chronic hemodialysis patients from two governmental and three private hemodialysis centers. Demographic information of hemodialysis was collected. The status of HBsAg and anti-HCV was assessed by using ELISA method by separating serum from collected blood sample and screened for the presence of HBsAg and anti-HCV antibody in a period of April-May 2016.

Results: In this study a total of 253 patients were recruited of whom 74.3% were men and the remaining 25.7% were females. HBsAg was positive in 1.2% (n=3/253) of the patients, anti- HCV antibodies were detected in 2.8% (n=7/253), 4% of patients had markers of at least one viral infection markers and 0.4% (n=1) were positive for both HBV and HCV infection.

Conclusion: In our study done, the prevalence of HBV and HCV infections in hemodialysis centers in Addis Ababa, Ethiopia was lower. Even if, history of blood transfusion and the number of blood units transfused might be a risk factor for HBV and HCV gaining, further studies are needed to assess the role of demographic and clinical risk factors in the Hemodialysis patients.

Keywords

Hemodialysis, Hepatitis B virus, Hepatitis C virus

Introduction

Hepatitis viruses cause potentially life-threatening inflammation of the liver, characterized by acute and chronic forms of liver disease. According to 2013 World Health Organization (WHO) global health impact report of viral hepatitis, more than 240 and 150 million populations were affected by chronic liver disease due to HBV and HCV, respectively [1]. Africa has the second largest number of chronic HBV carriers after Asia and is considered as a region of high endemicity. In Ethiopia, the overall prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) among the general population was 7.4% and 3.1% respectively [2].HBV is partially double stranded DNA, and it is highly prevalent in hemodialysis patients. The high levels of prevalence of HBV infection is mainly due to impact of dialysis and transfused blood units to these patients [3,4].

HCV infection remains frequent in patient receiving long-term dialysis both in developed and less developed countries. Natural history of HCV infection in dialysis patients remains incompletely understood; controversy continues even in patients with intact kidney function. Defining the natural history of HCV remains difficult for several reasons: the disease has a very long duration, it is mostly asymptomatic, and determining its onset may be difficult. Additional factors can modify the course including co infection with HBV, HIV and alcohol use [5]. HBV and HCV infections are the most important causes of morbidity and mortality in haemodialysis patients [5,6]. Following cardiovascular diseases and bacterial infections, viral hepatitis is the most frequent disease resulting in a complication of hemodialysis treatment [6].

Different infection prevention protocols have changed the incidence of viral hepatitis. For instance, screening of blood donors, erythropoietin therapy, isolation of HBV positive patients, use of dedicated dialysis machines, improved disinfectant procedures, regular surveillance for HBV infection and active HBV vaccination before entering dialysis program [7].

Chronic HD patients have high risk for infection, due to prolonged vascular access. In an environment where multiple patients receive dialysis concurrently, repeated opportunities exist for person-to-person transmission of infectious agents, directly or indirectly via contaminated devices, equipment and supplies, environmental surfaces, or hands of personnel. Furthermore, HD patients are immunesuppressed [8]. However, HD taken place in various health facilities found in Ethiopia ,no existing data is available regarding on prevalence of HBV and HCV done among HD patients in Addis Ababa. Therefore, this study aims to estimate the prevalence of HBV, HCV among HD patient’s in Addis Ababa in the period from April-May 2016.

Materials and Methods

A cross sectional prospective study was conducted in two hospitals (AFTGH , Bethel ), and three higher clinics (Santa, Tom , Tsigereda) in Addis Ababa, Ethiopia, from April-May 2016 by collecting a total of 253 blood samples. Ethical approval was obtained from Departmental Ethics and Research committee of the department of Medical Laboratory Science, College of Health Science, and School of Allied Health Science of Addis Ababa University. Informed consent was found from study subject.

▪ Measurement and data collection

To ensure proper data collection, close ended, multiple choice based questionnaire was designed both in English and local language which was completed by the principal investigator or/and HD staffs via patient interview. The collected data includes age, sex, education level, residency; time spent on HD, the number of blood units transfused and HBV vaccination. Reagents which are prequalified by WHO and with sensitivity and specificity of above 90% were revalidated and verified before use. Finally we used a reagent that gives us a sensitivity of 96% and a specificity of 97% for both HBV and HCV testing.

Before the start of the Hemodialysis procedure 5 ml venous blood was collected at the spot. The blood sample was allowed to stand for sufficient time for separation of serum. The sample was then centrifuged and serum was separated and preserved at -20°C.The next day the serum sample were transported to AFTGH and tested for HBV and HCV by fully automated Immunoassay analyzer (ARCHITECT i1000SR Abbott park, Illinois, U.S.A) using ready-made reagents for HBsAg and anti- HCV. The presence or absence of Ag and Ab in the sample was determined by comparing the chemilumenecent signal in the reaction to the cut off signal determined from an active calibration. If the chem.-illumencent signal in the specimen is greater than equal to the cutoff signal the sample is considered reactive. The positive were rechecked and negative samples were randomly reexamined for confirmation. The results were tabulated and analyzed.

Data analysis and interpretation

The collected data were entered and analyzed using the statistical package for social sciences software (SPSS v20.0;IBM Crop, Armonk, NY, U.S.A) and also organized and summarized in terms of frequency and the results of the study presented in a descriptive statics.

Results

A total of 253 patients were recruited, of these, 34.4% (n=87) were from Tom higher clinic 20.2% (n=51) were from Santa higher clinic, 18.6% (n=47) Bethel teaching hospital, 17.8% (n=45) Tsegereda higher clinic and the remaining 9.0% (n=23) Armed force teaching Hospital.

Socio-demographic characteristics of the respondents

From 253 study participants 74.3% (188/253) were males and 25.7 % (65/253) were females resulting in overall male to female ratio of about 3:1. According to sex distribution, males took the higher proportion in all age groups. Female participants observed higher in age 40-49 years relative to the other age groups. The mean age of the participants was 48.94 years ± 16 SD, with range from 18 to 89 years (Figure 1). In relation to marital status 74.7% (189/253) were married, 17.8% (45/253) were single and 2% (5/253) divorced, whereas the remaining 1.2% (3/253) was widow.

Regarding educational status the study revealed two extremes; in which 28.5% (72/253) of the study participants had above grade 12 education and 5.1% (13/253) were not received formal education. The prevalence of HBsAg and anti- HCV Ab in relation with socio-demographic characteristics are shown in (Table 1).

Table 1. The prevalence of hbsag and anti-HCV Ab in relation with socio-demographic characteristics in Army and Bethel hospital, Santa Tom and Tsegereda higher clinics, April –May 2016.

Magnitude and distribution of hepatitis B and C infection by age, sex, occupation marital status

As shown Table 1, in detecting HBsAg from serum sample the prevalence of HBsAg in hemodyalisis patients was 1.2% (3/253), and prevalence rate in males is 1.6 % (3/188) .The prevalence of HBV by specific age group was highest 5% (2/40) in the age group of 60-69 and was lowest (0%) in the other age groups except 1.3% (1/77) in the age groups 40-49.In addition ,in examining ant- HCVantibody the prevalence in HD patients was 2.8% (7/253), sex specific rate was lower in males 2.7% (5/188) than females 3.1% (2/65) .And higher prevalence of HCV is shown in specific age group of 40-49 which is 5.5% (4/73), the lowest (0%) counted in age groups >70 years, 4% (1/25) in the age groups<30, and 4.4% (1/23) in age group of 30- 39 is seen. Regarding, occupational distributions of HBsAg, and anti-HCV antibody positivity was found which is higher among self-employed 3.45% (3/86).Concerned on educational status acquisition of HBV and HCV is similar result was found, with an education level above grade twelve with a frequency of 2/72 (2.7%) and patients who can read and write 1/35 (2.8%). In relation to living area 0.79% (2/253) was positive for both HBsAg and anti-HCV antibody respectively in rural dwellers, and in urban dwellers 0.39% (1/253)HBsAg and 2.0% (5/253) wasgotten. With regard to marital status higher number of positivity was scored by singles with a prevalence of 0.79% (2/253) compared to married 0.39% (1/253) for HBsAg and higher anti-HCV antibody is detected in married individuals 2.4% (6/253) than single status 0.39% (1/253). The assessment of hepatitis C prevalence among hemodialysis patients was made by detecting anti-HCV Ab. The presence of this marker was taken as measure of infection. Seven 7/253 (2.8%) of the study participants were positive for anti-HCV antibody.

Prevalence of HBV and HCV co-infection

In this study 0.4% (1/253) of the participants was positive for both sero-markers HBsAg and Anti-HCV. The gender profile for these participants, who have both HBV and HCV infections, showed a male aged within 60-69 years (Table 2).

Table 2. The prevalence of HBV/HCV co-infection among HD patients in Army and Bethel hospitals, Santa, Tom and Tsigereda higher clinics, April– May 2016

Haemodialysis center services

In all of the centers, new cases of ESRD patients are tested for HBsAg and anti- HCV before initiation of HD and according to the result they are directed to the suitable HD area and machine within the center. Study participants in this study had been attending the procedure from 4 weeks to 4 years time duration. HD centers operate in two shifts; the morning shift was from 8 to 12 A.M, the noon shift from 12 A.M to 4 P.M. Physicians prescribe the frequency of HD for each patient accordingly. Most of study participants undergo two HD sessions per week (54.9%), followed by three HD sessions (43.5%) and the minimum number of sessions was one per week (1.6%) (Table 3).

Table 3. Time Duration of HD sessions in the five HD centers Addis Ababa, Ethiopia April-May 2016

Medical History of HD Patients

Among study participants 58% (147/253) had history of Hypertension, followed by 21.4% (55/253) had both Hypertensive and Diabetic cases and the remaining 11.2% (28/253) was Diabetic. Table 4 illustrates distribution of medical history of patients under hemodialysis at the five HD centers.

Table 4. The distribution of medical history of patients under hemodyalisis in Army and Bethel hospital,Santa Tom and Tsegereda higher clinics, Apri–May 2016.

Discussion

Viral hepatitis remains a major hazard for both patients and medical staffs of HD units. HCV became the major form of viral hepatitis among HD patients especially after the decline in incidence of HBV infection due to several factors including vaccination and screening of transfused blood for HBV [9]. As a case in point different studies made in different countries attests to this. For example, high prevalence of HBV (2.6%) and HCV (31.1%) in maintenance hemodialysis patients [10] was reported in Libya, HCV prevalence rates of 7% and 22% in HD patients have also been reported in Iran [7] and Palestine [9] respectively, and 7.8% HBV prevalence rate reported in Cameron [8]. Similarly, different studies conducted in Ethiopia found that Hepatitis B and C virus infections are significant community health problems in the country [10-14]. Contrary to these, the current study found low prevalence rate of HBV (1.2%) and HCV(2.8%) as compared from the general population which is 7.4% for HBV and 3.1% for HCV [15]. In addition infections among patients under hemodialysis in comparison to the results of the studies highlighted above.

Different studies confirmed that length of HD and use of shared machine was associated with high HBV and HCV acquisition in HD patients [5,7]. In this study low prevalence of HBV and HCV among hemodialysis patients was relatively low as compared to the Ethiopian general population and the other hemodialized patients in other part of the world as we mentioned above, may be due to the shorter duration of patients under hemodialysis procedure and separated usage of HD machine. Moreover, all of the five HD centers follow similar procedures in the use of disposable needle for artery-vein fistula, and precautions to prevent the exposuretonosocomial infection through avoidance of sharing multidose vials or blood contact equipment like filters and different tubing; this could be another probable cause.

Age distribution of ESRD patients in this study showed half of the cases were below fifty years of age. A comparable age distribution and results was seen in others studies [7,16]. A high prevalence of HBV was recorded in the age grup 60-69 with a prevalence of 4.9% (2/41) while in our finding it was 5% (2/40). The reason could be related with the low immunity of the age group to infection with the hepatitis viruses.

In terms of sex specific the frequency of HBV and HCV prevalence on HD patients was higher among males than females. This is also consistent with studies made in Iran. The greater frequency of ESRD and HBV infection in males as compared to females could be a reflection of the tendency of males more coming for treatment than females in our setting. Comparable results were reported in a number of studies concerning HBV infection, Ethiopia 4.9% (273/5592) in males and 3.3 % (25/769) in females [14]. Related to the presumed cause of ESRD the majority 56.5% related with Hypertension in the study population.

In HD centers HCV is a major problem and is prevalent in both pre-dialysis population and more significant in patients on maintenance of HD [15-17]. Because HCV infections are of special public health concern and the infected person has a potential reservoir for its transmission, the prevalence of HCV among HD patients is higher (2.8%). This rate is comparable with the study done in different countries in which prevalence was between (3%-7%) [18-21] and lower than of Brazil (46.7%) [22]. In summary this study has found relatively low prevalence of HBV and HCV in HD patients. Using ELISA test kit for analysis of hepatitis B and hepatitis C than commercially available rapid test kits gives strength and Hemodialysis patients with occult HBV infection were not identified, and limited number of study sites was the limitation of the study.

Conclusions

This study has found lower prevalence of hepatitis B and hepatitis C infection among hemodialysis patients visiting five selected HD centers.

Recommendations

1. Adherence to comprehensive infection control program include infection control practices, effective follow up procedure ,routine serological testing and immunization, surveillance, training and education.

2. Further studies are recommended to investigate associated risk factors regarding the prevalence of HBV and HCV in HD patients

3. Practice of health workers in HD centers should be investigated regarding infection transmission.

4. Finally further studies are needed to define hepatitis virus’s genotypes between HD patients.

Declarations

The study protocol was approved by Departmental Ethics and Research committee of the department of Medical Laboratory Science, College of Health Science, and School of Allied Health Science of Addis Ababa University. Permission was obtained from the health facilities administrator. Subject was recruited after they become informed about the objectives and use of the study and after they give informed consent patient results are confidential only respective individuals was allowed to evaluate or see result.

Consent to Publish

Not applicable.

Availability of Data

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interest

All authors declare that they have no computing interest.

Funding

Not applicable

Author’s Contribution

Shemsu Kedir: Conceived the study, conducted data collection, data cleaning and analysis.

Negash nur Ahmed, Sisay Kebede: Contributed to the design and conduct of the study.

Mulusew Getahun: Conducted the statistical analysis and wrote the manuscripts.

Tassew Arega: Conducted the statistical analysis and wrote the manuscripts.

Ahmed Mohamed Abdi conducted the statistical analysis and wrote the manuscripts.

Acknowledgment

I would like to thank Ato Kassu Desta and W/ ro Mintewab Hussen for their valuable and constructive comments during proposal approval.

My heartfelt appreciation goes to Ato Sissay Kebede, W/t Mazza Biruu and W/ro Tiblet G/ Tsadike for their material support.

I would like to thank staffs of the participating hospitals and higher clinics specially dyalsis and laboratory staffs and all participants in this study for supporting in data collection and sample preparation.

References

1. WHO. Global policy report on the prevention and control of viral hepatitis in WHO Member States 536 (2013).
2. Belyhun Y, Maier M, Mulu A, et al. Hepatitis viruses in Ethiopia: A systematic review and meta-analysis. BMC. Infect. Dis. 16(1), 761 (2016).
3. Niloofar N, Mnocher M, Ali R. A Study on genotype of hepatitis B virus among hemodialysis patients in Khuzestan Province. Jundishapur. J. Microbiol. 4(2), 65-70 (2011).
4. Panga B.C. Seroprevalence of hepatitis B surface antigen and associated risk factors among pregnant women attending antenatal care clinic in Moshi municipality, Kilimangaro region. 8-10 (2012).
5. Fabrizio F. Hepatitis C Virus infection and dyalisis: 2012 update. ISRN. Nephrol. 11, 43-49 (2013).
6. Ibrahim AN, I Elhag W. Occult HBV infection in sudanesse hemodialysis patients. Laboratory. Medicine. Journal. 1(1), 43-49 (2013).
7. Nassiri Toosi M, Larti F, et al. Prevalence of viral hepatitis in hemodyalisis patients in Tehran, Iran. J. Gastrointestin. Liv. Dis. 17(2), 233-239 (2008).
8. MP Halle, HN Luma, E Temfac, et al. Prevalence of hepatitis B surface antigen and anti HIV antibodies among patients on maintenance hemodyalisis in Douolla-Cameron. Health. Sci. Dis. 14(3), (2013).
9. El-Otool AK, Elmanama AA, Ayesh BM. Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in gaza strip, Palastine. Virol. J. 7,210 (2010).
10. Yimer K. Serological and molecular characterization of Hepatitis B, C and D Viruses Infections among Health Professionals in Public Hospitals, Addis Ababa, Ethiopia. A thesis submitted to Addis Ababa University digital library. Unpublished (2003.).
11. Tessema B, Yismaw G,  Kassu A, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia. BMC. Infect. Dis. 10(1), 111-117 (2010).
12. Ayele W, Nokes DJ, Abebe A, et al. Higher Prevalence of Anti-HCV Antibodies Among HIV Positive Compared to HIV-Negative Inhabitants of Addis Ababa, Ethiopia. J. Med. Virol. 68(1), 12-17 (2002).
13. Tiruneh M. Seroprevalence of multiple sexually transmitted infections among antenatal clinic attendees in Gondar Health Center, northwest Ethiopia. Ethiop. Med. J. 46(4), 359-366 (2008).
14. Gelaw B, Mengistu Y. The prevalence of HIV, HCV and Malaria parasites among blood donors in Amahara and Tigray regional states. Ethiop. J. Health. Dev. 22(1), 3-7 (2008).
15. Amidu N, Alhassan A, Obirikorang C, et al. Sero-prevalence of hepatitis B surface (HBsAg) antigen in three densely populated communities in Kumasi, Ghana. J. Med. And. Biomed. Sci. 1(2), 59-65 (2012).
16. Makondo E, Bell TG, Kramvis A. Genotyping and molecular characterization of hepatitis B virus from HIV infected individuals in southern Africa. PLoS. One. 7(9), (2012).
17. Hughes J, Mahy B. Recommendations for prevention and control of hepatitis C virus infection and HCV-related chronic disease. CDC. MMWR. Recomm. Rep. 47(19), 1-39 (1998).
18. Thaiar FA Kadhum. Seroepidemological and molecular study of HBV in Al-rusafa sector of Baghdad. 30-34 (1987).
19. Held PJ, Brunner F, Odaka M, et al. Five year survival for end-stage renal disease patients in the United States, Europe and Japan, 1982 to1987. Am. J. Kidney. Dis. 15(5), 451-457 (1990).
20. Schon S, Ekberg H, Wikstrom B, et al. Renal replacement therapy in Sweden. Scand. J. Urol. Nephrol. 38(4), 332-339 (2004).
21. Wiam AA, Christopher WM, Maarten WT. Heptatis B and C infection in hemodialysis patients in Libya: prevalence, incidence and risk factors. BMC. Infect. Dis. 12(1), 265 (2012).
22. Recommendations for preventing transmission of infections among chronic hemodialysis patients. CDC MMWR. Recomm. Rep. 50(5), 1-43 (2001).